Genmab — November 2014
-
Conclusions: The combination of ofatumumab and bendamustine has promising activity in elderly pts with high risk MCL, with superior CR rates compared to historical chemo-immunotherapeutic regimens. Among 12/16 evaluable pts (3 too early, 1 withdrew) in the O-B arm; overall response rate was 92%; CR rate was 67%, PR rate 25%.
-
igen flotte flotte data i MCL. Ibrutinib har jo sat sig på den indikation
-
som spændende om ofa+ibrutinib vil være stærke her
-
I øvrigt ser det også lovende ud for humax-TAC-ADC: these data clearly demonstrate the potent antitumor activity of ADCT-301 against CD25-expressing hematological tumors and warrants the rapid development of this agent into the clinic.https://ash.confex.com/ash/2014/webprogram/Paper71609.html
-
Jeg hører lige CC igen. Spændende det David Eatwall siger. De skal indenfor den nærmeste fremtid afgøre om de vil "opt-in" og holde 50% ejerandel af Humax-TAC-ADC
-
Så kan lyde som om der måske er en IND der næste år og genmab så skal beslutte inden om de vil være med til at dele udgifterne?
-
-
https://ash.confex.com/ash/2014/webprogram/Paper75657.html Bispecific CD20 fra
-
Ja ADC har ambitioner: http://www.adctherapeutics.com/news/2014/09/adc-therapeutics-expands-team
-
Alt går giodt
-
godt*
-
Bank of America / Merill Lynch hæver til 293
-
614 er deres bluesky kursmål
-
de er flinke ved ARzerra. 27 kurspoint
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind